YWYang Wang

Yang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yang Wang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Chun Qiao

    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China

    1 shared publication
  • Fangrong Zhang

    Key Laboratory of Gastrointestinal Cancer, Ministry of Education, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, China

    1 shared publication
  • Hui Li

    Antibody Engineering Laboratory, School of Life Science & Technology, China Pharmaceutical University

    1 shared publication
  • Jialing Cai

    Antibody Engineering Laboratory, School of Life Science & Technology, China Pharmaceutical University

    1 shared publication
  • Jingjing Xu

    Antibody Engineering Laboratory, School of Life Science & Technology, China Pharmaceutical University

    1 shared publication
  • Juan Zhang

    China Pharmaceutical University

    1 shared publication

Latest Publications

  • B7–H1 agonists suppress the PI3K/AKT/mtor pathway by degrading p110γ and independently induce cell death

    by Ling Chen, Ping Hou, Yu-Lian Zou, Yang Wang, Lin-Lin Zhou, Li Hu, Yan Hu, Qiu-Yu Zhang, Li-Ping Huang, Lin Lin


  • Open Access

    Metabolic Regulation of Hepatitis B Virus Infection in HBV-Transgenic Mice

    by Wenning Lan, Yang Wang, Zixiong Zhou, Xia Sun, Yun Zhang, Fangrong Zhang

    Hepatitis B virus (HBV) infection is a worldwide health burden. Metabolomics analysis has revealed HBV-induced metabolism dysregulation in liver tissues and hepatocytes. However, as an infectious disease, the tissue-specific landscape of metabolic profiles of HBV infection remains unclear. To fill this gap, we applied untargeted nuclear magnetic resonance (NMR) metabolomic analysis of the heart, liver, spleen, lung, kidney, pancreas, and intestine (duodenum, jejunum, ileum) in HBV-transgenic mice and their wild-type littermates. Strikingly, we found systemic metabolic alterations induced by HBV in liver and extrahepatic organs. Significant changes in metabolites have been observed in most tissues of HBV-transgenic mice, except for ileum. The metabolic changes may provide novel therapeutic targets for the treatment of HBV infection. Moreover, tissue-specific metabolic profiles could speed up the study of HBV induced systemic metabolic reprogramming, which could help follow the progression of HBV infection and explain the underlying pathogenesis.


  • BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma

    by Yang Wang, Hui Li, Wei Xu, Mingzhu Pan, Chun Qiao, Jialing Cai, Jingjing Xu, Min Wang, Juan Zhang

    B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein expressed on malignant plasma cells of patients with multiple myeloma (MM), and it is a defined therapeutic target. Major histocompatibility complex class I-related chain A (MICA) is frequently expressed in lymphoproliferative malignancies including MM. MICA activates natural killer (NK) cells and costimulates T cells by interaction with its immunoreceptor NK cell receptor G2D (NKG2D). Nonetheless, during full-blown MM, tumor cells promote efficient MICA shedding, which evokes NKG2D internalization and immune suppression. To enhance the directional killing efficacy of immune cells against myeloma cells, we constructed a novel bispecific antibody 2A9-MICA and explored its potential antimyeloma activity against MM. 2A9-MICA consists of human MICA extracellular region and a single–chain antibody fragment (scFv) that targets BCMA generated by phage display technology. In vitro, 2A9-MICA activated NK cell-mediated cytotoxicity and induced NK cells to kill BCMA–positive human myeloma cells. Moreover, in BCMA-positive, MM-bearing nude mice, 2A9-MICA specifically targeted tumor tissue, where it effectively recruited immune cells and inhibited tumor tissue growth showed superior antitumor activity. Taken together, bispecific antibody 2A9-MICA provides a new approach for MM-targeting immunotherapy and has attractive potential for clinical applications.